Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Deciphering Obesity Management Guidelines
Updates on Emerging GLP-1 Receptor Agonists
Glaucoma Progression.
Progression After Cancer Immunotherapy in Advanced NSCLC
SGLT2 Inhibitors and Their Clinical Impact:
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
What Comes Second?.
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
SGLT2 Inhibitors and CV Outcomes
Chronic Idiopathic Urticaria
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Tailoring Hemophilia Prophylaxis Therapy
GLP-1 Receptor Agonists: How Early Is Appropriate?
T2DM and CV Outcomes Trials: A Deep Dive!
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Basics of Immunotherapy Potential Therapeutic Targets.
Improving Management of Type 2 Diabetes in Hispanic/Latino Patients
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Case Study Role of DPP-4 Inhibitors
Tackling CV Risk in T2DM.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Early and Intensive T2D Management:
Breaking Down the CVOTs
Evaluating Next-Generation BTK Inhibitors
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Learning Objectives Metabolic Abnormalities Associated With T2D.
CV Outcomes and Adherence With GLP-1 RAs
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Oral Combination Therapy for T2D
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Insulin in Diabetes Management: Effective Patient Selection Is Key
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Overall Health
Getting PPG Under Control
New Options for the Treatment of Hepatocellular Carcinoma
What's New in Oral Combination Therapy for Type 2 Diabetes?
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
In the Know.
Presentation transcript:

Case-Based Examination of Treatment Options in Type 2 Diabetes Management

Patient-Centric Focus of 2016 AACE/ACE and 2015 ADA/EASD Recommendations

Therapeutic Algorithm for Glycemic Control*

Case 1 History

Case 1 Physical Examination

Case 1 Laboratory Tests

Case 1 Diagnoses

Case 1 Treatment Considerations

SGLT2 Inhibitors

SGLT2 Inhibitors (cont)

Case 2 History and Laboratory Tests

Case 2 Treatment Considerations

DPP-4 Inhibitors

Case 3 History

Case 3 Physical Examination

Case 3 Laboratory Tests

Case 3 Considerations and Goals

Case 3 Treatment Options

Comparison of Glycemic Efficacy in Head-to-Head Trials of GLP-1 RAs

β-Cell Preservation

CV Effects of GLP-1 RAs

GLP-1 RAs Patient Education

GLP-1 RAs Fixed Dose Combinations (FDCs)

Concluding Remarks

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.